Beta-agonists can stimulate beta-receptors on airway smooth muscle to produce bronchodilator effects and are the basis for COPD, while beta-blockers can counteract the toxicity of catecholamine adrenergic transmitters, especially through beta1 receptors mediated cardiotoxicity, as well as anti-hypertension, anti-myocardial ischemia, blocking the renin-angiotensin-aldosterone system by inhibiting renin release, improving cardiac function and increasing left ventricular ejection fraction, antiarrhythmic and other effects, is the standard treatment of many CVD drugs. This evidence concerns the gene REN and chronic obstructive pulmonary disease.